COMPLEXE URINAIRE
Food supplement declared in France, declaration No 2018-10-170
COMPLEXE URINAIRE is a food supplement declared in France. Status: withdrawn from the market on 31 August 2021. 1 point in its composition requires a check (prohibited substance, dose or novel food).
- Brand
- not provided
- Food business operator placing the product on the market
- Biofarma France (Sérent - Laboratoire Pierre Caron)
- Status
- Withdrawn from the market on 31 August 2021
- Form
- Capsule
- Daily dose
- 2 gélules par jour
- Directions for use
- Prendre 2 gélules par jour avec un grand verre d’eau.
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, Children (under 12), Pregnant women, Kidney failure, Prolonged use
- Objectives stated by the manufacturer (these are not authorised claims)
- Urinary system
Declaration 158742, procedure Article 16. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Vaccinium macrocarpon Aiton | Fruit | Autre extrait sec | 360 mg |
| Erica cinerea L. | Sommités fleuries | Extrait sec aqueux | 100 mg |
| Arctostaphylos uva-ursi (L.) Spreng. | Feuille | Extrait sec aqueux | 100 mg |
| Coriandrum sativum L. | Fruit | Poudre (de plantes séchées ou broyées) | 100 mg |
Additives
E470b, E551, E171, E464
Other ingredients
maltodextrine
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Label warnings
Déconseillé chez les enfants, les adolescents, les femmes enceintes et allaitantes, ainsi que chez les personnes souffrant d'insuffisance rénale ; ne pas dépasser une semaine d'utilisation.
Regulatory points
- À vérifier
The composition lists additive E171 (titanium dioxide), removed from the list of additives allowed in food, supplements included: since 7 August 2022, a supplement containing it can no longer be placed on the market in the Union.
Source: Regulation (EU) 2022/63: titanium dioxide (E171) removed from the food additives allowed in the EU, règlement (UE) 2022/63.
- Information
Withdrawn from the market on 31 August 2021, according to Compl'Alim.
Source: Compl'Alim, food supplement declarations (France).
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Vaccinium macrocarpon Aiton
Read the warning, when it applies and the studies cited
CRANBERRY - VACCINIUM MACROCARPON
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).
Sources cited by Health Canada (2)
- Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomised trial
- Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).
Sources cited by Health Canada (4)
- Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Case report
- Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.
Condition of application: (Recurrent) urinary tract infection.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 27 March 2026
DRIED CRANBERRY JUICE
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).
Sources cited by Health Canada (2)
- Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomised trial
- Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).
Sources cited by Health Canada (4)
- Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Case report
- Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.
Condition of application: (Recurrent) urinary tract infection.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
- Arctostaphylos uva-ursi (L.) Spreng.
Read the warning, when it applies and the studies cited
Bearberry - Arctostaphylos Uva-Ursi
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Applies to products providing 60 milligrams or more of dried leaves and/or products providing 20 milligrams or more of Arbutin, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver disorder, fever, painful urination (dysuria), spasms, or blood in urine (EMA 2018; Duke 2002; Newall 1996).
Sources cited by Health Canada (2)
- EMA 2018: EMA/HMPC/750269/2016. European Union herbal monograph on Arctostaphylos uva-ursi (L.) Spreng., folium. London (GB): European Medicines Agency: Committee on Herbal Medicinal Products (HMPC); 2018 January 30. [Accessed 2024 June 11]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-arctostaphylos-uva-ursi-l-spreng-folium-revision-2_en.pdf
- Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A guide for health-care professionals. London (GB): The Pharmaceutical Press; 1996.
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Contraindications
Do not use if you are pregnant or breastfeeding (EMA 2018; Brinker 2010; ESCOP 2003; WHO 2002; Blumenthal 2000; Mills and Bone 2000; Bradley 1992).
Sources cited by Health Canada (8)
- Blumenthal M, Goldberg A, Brinckmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Newton (MA): Integrative Medicine Communications; 2000.
- Bradley PR, editor. British Herbal Compendium Volume 1: A Handbook of Scientific Information on Widely Used Plant Drugs - Companion Volume 1 of the British Herbal Pharmacopoeia. Bournemouth (GB): British Herbal Medicine Association; 1992.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2018: EMA/HMPC/750269/2016. European Union herbal monograph on Arctostaphylos uva-ursi (L.) Spreng., folium. London (GB): European Medicines Agency: Committee on Herbal Medicinal Products (HMPC); 2018 January 30. [Accessed 2024 June 11]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-arctostaphylos-uva-ursi-l-spreng-folium-revision-2_en.pdf
- ESCOP 2003: European Scientific Cooperative of Phytotherapy. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition completely revised and expanded. Exeter (GB): European Scientific Cooperative on Phytotheraphy; 2003.
- Mills S, Bone K. Principles and Practice of Phytotherapy, Modern Herbal Medicine. Edinburg (GB): Churchill LYes Soivingston; 2000.
- WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 3. Geneva (CH): World Health Organization; 2002.
- OMS 2002: Organisation mondiale de la santé (OMS). Monographs on Selected Medicinal Plants : Volume 3. Genève (CH): Organisation mondiale de la santé; 2002.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- COMPLEXE URINAIRE ORFITO, declared in 2019 : different composition: 8 ingredient(s) added, 8 missing
- COMPLEXE URINAIRE ERIC FAVRE ORGANIC, declared in 2016 : different composition: 5 ingredient(s) added, 9 missing
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.